Malorie Meshkati, MD

Matthew Drago, MD is a Pediatrics provider with Mount Sinai Health System, treating patients in the New York area. Dr. Drago is committed to compassionate, coordinated care that supports patients throughout the diverse communities we serve.

I see patients at the Dubin Breast Center. I am dedicated to caring for the entire patient with breast cancer: from oncologic management, to supportive care, symptom management and psychological support. I work closely with an interdisciplinary team including nurses, social workers, psychologists, radiologists and surgeons. I have an interest in treating all stages of breast cancer and incorporating the latest evidence based data to treat patients with cancer. I actively take part in clinical trials at the Dubin Breast Center. I have a research interest in improving quality delivery of cancer care to each individual patient and how we can improve upon that in our every day practice to improve cancer outcomes.

I am a medical oncologist specializing in the care of patients with breast cancer. As a physician-scientist, I also lead a research laboratory that is focused on developing targeted therapies tailored for specific breast cancer subtypes and for individual patients. I have a particular interest in better understanding triple negative breast cancers, with the goal of integrating genetic analysis to the development of improved treatments for our patients. I am co-PI of the Breast Tumor Biospecimen Repository, which is a bank of patient breast tumors; analysis of these tumors will provide insights into the genetic changes that determine sensitivity to specific targeted therapies for breast cancer. I am also co-PI of a study investigating the use of patient-derived xenograft models as a model for chemotherapy treatment sensitivity for patients with triple negative breast cancers; if successful, these models may be used in the future to help us better tailor treatments for individual patients. My research laboratory has identified several new candidate therapeutic targets for Her2+ and triple negative breast cancers resistant to current treatments, and we are working to translate our findings to clinical studies and trials. I am a member of the American Society of Clinical Oncology and the American Association for Cancer Research.